Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04827576 · ClinicalTrials.gov registry record · Phase 2
Study of Magrolimab in Patients With Solid Tumors
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT04827576 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 106 participants.
The verdict
NCT04827576, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with docetaxel in participants with solid tumors.
Interventions
- DRUG Docetaxel
- DRUG Magrolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2024-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04827576
The ClinicalTrials.gov registry entry for NCT04827576 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT04827576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04827576 about?
NCT04827576 is a clinical study titled "Study of Magrolimab in Patients With Solid Tumors". The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with docetaxel in participants with solid tumors.
What is the current status of trial NCT04827576?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2021-10-01. Estimated completion is 2024-10-01.
What interventions are being tested in trial NCT04827576?
The interventions under investigation include: Docetaxel (DRUG), Magrolimab (DRUG).
Who is sponsoring clinical trial NCT04827576?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.